About Us  

IMDx’s competitive advantage is in the production of superior performing tests with a significantly faster time to market. Embedded in our approach is a bioinformatics process that uses mathematical algorithms to predict test success and failure and the simulation of real life conditions, such as contamination or genetic mutations that can impact a test’s clinical performance. IMDx’s current pipeline includes proprietary nucleic acid (DNA or RNA) tests for Real Time PCR. IMDx has a pipeline of single test (singleplex) and multi-test (multiplex) diagnostic solutions for a wide range of human diseases. We have built our product candidate portfolio through internal discovery and are advancing our product candidates through in-house R&D. The quality and breadth of our product candidate pipeline, platform-agnostic approach, scientific team and strategic collaborations enable us to be a leader in the high value diagnostic content market.IMDx’s competitive advantage is in the production of superior performing tests with a significantly faster time to market. Embedded in our approach is a bioinformatics process that uses mathematical algorithms to predict test success and failure and the simulation of real life conditions, such as contamination or genetic mutations that can impact a test’s clinical performance. IMDx’s current pipeline includes proprietary nucleic acid (DNA or RNA) tests for Real Time PCR. IMDx has a pipeline of single test (singleplex) and multi-test (multiplex) diagnostic solutions for a wide range of human diseases. We have built our product candidate portfolio through internal discovery and are advancing our product candidates through in-house R&D. The quality and breadth of our product candidate pipeline, platform-agnostic approach, scientific team and strategic collaborations enable us to be a leader in the high value diagnostic content market. 

A privately held company based in Cambridge, MA, IntelligentMDx has been named a Business Leader in Medical Diagnostics by Scientific American magazine within the Scientific American 50.  The quality and breadth of our product candidate pipeline, platform-agnostic approach, scientific team and strategic collaborations is enabling us to be a leader in the high value diagnostic content market.

Download Company Brochure